Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy
Go back to Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Niño Jesús in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy| Orgenesis, Inc. NEW (NASDAQ: ORGS) | Delayed: 0.52 +0.02 (4.00%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.50 | 52 Week High | $0.52 | |||
| Open | $0.51 | 52 Week Low | $0.24 | |||
| Day High | $0.52 | P/E | 10.40 | |||
| Day Low | $0.51 | EPS | $0.05 | |||
| Volume | 1,683 | |||||
